NCT03766763进行中（未招募）2 期
Preemptive Therapy With Venetoclax for High Risk Chronic Lymphoid Leukemia Stage A Patients, a Phase II Trial of the FILO
French Innovative Leukemia Organisation23 个研究点 分布在 1 个国家目标入组 82 人开始时间: 2019年5月22日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 82
- 试验地点
- 23
- 主要终点
- Complete response rate
研究概览
简要总结
Open label, single arm, multicenter phase II trial.
详细描述
Preemptive therapy with Venetoclax for high risk stage A Chronic Lymphoid Leukemia patients, a phase II trial of the FILO group.
PREVENE (PREemptive VENEtoclax) trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Established diagnosis of Chronic Lymphoid Leukemia by International Workshop Chronic Lymphoid Leukemia 2008 criteria with Matutes score Superior to 3, or Matutes score egal to 3 with CD200 positive and CD20 low
- •High risk Binet stage A, patients presenting at least 2 from 3 risk factors: Lymphocytosis Superior to 13 Giga per liter, CD38 positive, beta2 microglobulin Superior to 2.5 milligram per liter.
- •Only patients with unmutated status will be treated and followed according to the trial.
- •No prior chemotherapy, radiation or antibody treatment
- •Age Superior to 18 years
- •Life expectancy Superior to 6 months
- •Performance status 0 to 2
- •All parameters for risk stratification present
- •Possibility of follow-up
- •Adequate hepatic function per local laboratory reference range as follows: Aspartate transaminase and alanine transaminase Superior to 3.0 of upper limit of normal and Bilirubin inferior or egal to 1.5 of upper limit of normal (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin).
- •Willingness to accept highly effective methods of contraception for the duration of therapy and 12 months thereafter
- •Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin) or urine pregnancy test at Screening.
- •Sign (or their legally-acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study, including biomarkers, and are willing to participate in the study
排除标准
- •Binet Stage A patients with progressive disease according to International Workshop Chronic Lymphoid Leukemia 2008 criteria
- •Clinically apparent autoimmune cytopenia, in particular antiglobulin test positive hemolytic anemia (positive antiglobulin test without anemia is not an exclusion criteria)
- •Active secondary malignancy or chemotherapy/radiotherapy for any neoplastic disease other than Chronic Lymphoid Leukemia prior to the study
- •Medical condition requiring the long term (estimated to be more than one month) use of oral corticosteroids
- •Patient refusal to perform the bone marrow biopsy for evaluation points
- •Patients with active bacterial, viral or fungal infection
- •Subject is known to be positive for Human Immunodeficiency Virus
- •Evidence of other clinically significant uncontrolled conditions
- •Treatment with any other investigational agent or participating in another trial within 30 days prior to entering this study
- •A female patient who is pregnant or breast feeding
- •Concurrent severe diseases which exclude the administration of therapy
- •Richter's syndrome
- •Treatment with any of the following within 7 days prior to the first dose of study drug: Steroid therapy for anti-neoplastic intent, moderate or strong cytochrome P450 3A inhibitors, moderate or strong cytochrome P450 3A inducers
- •Administration or consumption of any of the following within 3 days prior to the first dose of study drug: grapefruit or grapefruit products, Seville oranges, star fruit.
- •Prior and concomitant therapy
- •Malabsorption syndrome or other condition that precludes enteral route of administration
- •Received a live viral vaccination within 6 months prior to the first dose of study drug. A significant history of renal, neurologic, psychiatric, endocrine, metabolic, immunologic, cardiovascular, or hepatic disease that, in the opinion of the investigator, would adversely affect the patient's participation in this study or interpretation of study outcomes
- •Major surgery within 30 days prior to the first dose of study treatment
- •History of prior other malignancy that could affect compliance with the protocol or interpretation of results
- •Not affiliated to social security
研究组 & 干预措施
ARM A VENETOCLAX
Experimental
VENETOCLAX
干预措施: Venetoclax (Drug)
结局指标
主要结局
Complete response rate
时间窗: 12 months
according to International Workshop Chronic Lymphoid Leukemia 2008 guidelines and with Minimal Residual Disease inferior to 0.01 percent (as determined by 8-color technique) in bone marrow at month 12.
次要结局
未报告次要终点
研究者
研究点 (23)
Loading locations...
相似试验
招募中
2 期
PREVENE : Preemptive therapy with Venetoclax for high risk CLL stage A patients, a phase II trial of the FILO2024-513718-37-00French Innovative Leukemia Organization45
进行中（未招募）
2 期
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)Multiple MyelomaNCT02899052AbbVie120
招募中
1 期
Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDSMyelodysplastic SyndromesAcute Myeloid LeukemiaNCT05342584Montefiore Medical Center99
招募中
2 期
BCL2i CLAG-M in R/R Acute Myeloid LeukemiaRelapsed or Refractory Acute Myeloid Leukemia (AML)NCT06660368H. Lee Moffitt Cancer Center and Research Institute52
已完成
1 期
Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell LymphomasDiffuse Large B-Cell LymphomaHigh Grade B-Cell LymphomaNCT03036904Weill Medical College of Cornell University31